A photo of Adam Nelson.

Member, Division of Bone Marrow Transplantation and Immune Deficiency

Assistant Professor, UC Department of Pediatrics



About Me


I specialize in the care of patients with bone marrow failure syndromes and those who require bone marrow transplants. I am also interested in the use of cellular therapy, particularly to prevent and treat viral infections in patients before or after transplant. I consider it a privilege to work with such a multidisciplinary team to deliver the best care for my patients.

I always wanted to work with children because any care we can give them early in life can have a huge impact in helping them live normal lives. I was particularly drawn to bone marrow transplant, as this field is constantly changing and adapting as new scientific breakthroughs are discovered. I value getting to follow my patients for the rest of their lives and see them grow up and have children of their own.

Originally from Australia, I came to Cincinnati Children’s thinking I would only be here for a year. But after seeing the wonderful care delivered here, I was fortunate enough to stay and continue to work with our dedicated team.

In my practice, I enjoy being an integral part of my patient's journey and accommodating the needs of the entire family throughout their treatment. I align the needs of my patients with the best clinical practices and the most up-to-date treatments available to ensure a good outcome.

When I’m not treating patients, I’m doing research. I received an award from the Fanconi Anemia Research Fund to investigate how to prevent the development of cancer in patients affected by Fanconi anemia, a disease that affects bone marrow. My colleagues and I are also looking at ways to prevent bone marrow failure (BMF), to treat some of the complications of BMF syndromes and to develop new targeted strategies to minimize toxicity associated with treatments. Additionally, we are working on ways to use T cells to prevent and treat new viral infections in patients with weakened immune systems, either after bone marrow transplant or after receiving a solid organ transplant.

When I’m not at work, I like spending time with family and friends. I also enjoy keeping active and occasionally doing 24-hour trail runs with like-minded crazy friends.

Academic Affiliation

Assistant Professor, UC Department of Pediatrics

Clinical Divisions

Bone Marrow Transplantation BMT, Cancer and Blood Diseases, Fanconi Anemia, Immune Deficiencies and Histiocytosis

My Locations

My Education

BMedSci: University of Sydney, Australia, 2002.

MBBS(Hons): University of Sydney, Australia, 2006.

Residency: Sydney Children's Hospital, Australia, 2011.

Fellowship: Sydney Children's Hospital, Australia, 2014.

BMT Fellowship: Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2015.

My Publications

Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients. Nelson, AS; Heyenbruch, D; Rubinstein, JD; Sabulski, A; Jodele, S; Thomas, S; Lutzko, C; Zhu, X; Leemhuis, T; Cancelas, JA; et al. Blood Advances. 2020; 4:5745-5754.

Chimeric Antigen Receptor T Cell Therapy in Patients with Multiply Relapsed or Refractory Extramedullary Leukemia. Rubinstein, JD; Krupski, C; Nelson, AS; O'Brien, MM; Davies, SM; Phillips, CL. Biology of Blood and Marrow Transplantation. 2020; 26:e280-e285.

Improving Oral Health and Modulating the Oral Microbiome to Reduce Bloodstream Infections from Oral Organisms in Pediatric and Young Adult Hematopoietic Stem Cell Transplantation Recipients: A Randomized Controlled Trial. Badia, P; Andersen, H; Haslam, D; Nelson, AS; Pate, AR; Golkari, S; Teusink-Cross, A; Flesch, L; Bedel, A; Hickey, V; et al. Biology of Blood and Marrow Transplantation. 2020; 26:1704-1710.

CCR5 inhibitor as novel acute graft versus host disease prophylaxis in children and young adults undergoing allogeneic stem cell transplant: results of the phase II study. Khandelwal, P; Fukuda, T; Teusink-Cross, A; Kashuba, AD M; Lane, A; Mehta, PA; Marsh, RA; Jordan, MB; Grimley, MS; Myers, KC; et al. Bone Marrow Transplantation. 2020; 55:1552-1559.

Complement inhibition does not impair the clinical antiviral capabilities of virus-specific T-cell therapy. Rubinstein, JD; Zhu, X; Lutzko, C; Leemhuis, T; Cancelas, JA; Jodele, S; Bollard, CM; Hanley, PJ; Davies, SM; Grimley, MS; et al. Blood Advances. 2020; 4:3252-3257.

Use of CD19-directed CAR T-Cell Therapy in an Infant With Refractory Acute Lymphoblastic Leukemia. Breese, EH; Krupski, C; Nelson, AS; Perentesis, JP; Phillips, CL. Journal of Pediatric Hematology/Oncology. 2020; Publish Ahead of Print.

Ibrutinib for the treatment of chronic graft-vs-host disease in pediatric hematopoietic stem cell transplant patients: A single-center experience. Teusink-Cross, A; Davies, SM; Grimley, MS; Chandra, S; Flannery, A; Dandoy, CE; Nelson, AS; Marsh, RA; Jacoby, B; Lane, A; et al. Pediatric Transplantation. 2020; 24.

Chimeric antigen receptor T-cell therapy in patients with neurologic comorbidities. Rubinstein, JD; Nelson, AS; Krupski, C; O'Brien, W; Taylor, JM; Badgett, TC; Huang, M; Davies, SM; Phillips, CL. Pediatric Blood and Cancer. 2020; 67.

Complement blockade for TA-TMA: Lessons learned from a large pediatric cohort treated with eculizumab. Jodele, S; Dandoy, CE; Lane, A; Laskin, BL; Laskin, B; Teusink-Cross, A; Myers, KC; Wallace, G; Nelson, AS; Nelson, A; et al. Blood. 2020; 26:S138-S138.

EBV-directed viral-specific T-lymphocyte therapy for the treatment of EBV-driven lymphoma in two patients with primary immunodeficiency and DNA repair defects. Rubinstein, JD; Burns, K; Absalon, M; Lutzko, C; Leemhuis, T; Chandra, S; Hanley, PJ; Keller, MD; Davies, SM; Nelson, A; et al. Pediatric Blood and Cancer. 2020; 67.